Abstract
Immunomagnetic separation with anti-CD34 monoclonal antibodies and paramagnetic microbeads has been used to enrich hematopoietic stem cells from human bone marrow (BM) or mobilized peripheral blood mononuclear cells (PBMNC). The introduction of this technique also constitutes a new principle of tumor cell purging. The efficiency in terms of purging tumor cells from PBMNC was evaluated in seven different experiments. Mobilized (chemotherapy and G-CSF) PBMNC were collected from patients with solid tumors (n = 6) and multiple myeloma (n = 1) by leukapheresis using an automated MNC separation system and contaminated with 1% (n = 5) or 10% (n = 2) tumor cells from different epithelial cell lines being CD34-negative. The cell mixture was sensitized with anti-CD34 (9C5) antibodies and sheep anti-mouse IgG1 paramagnetic microspheres and enriched for CD34+ cells using an Isolex 50 magnetic separator. Purity of CD34+ cells was studied by flow cytometry (FACScan) and tumor cell depletion was evaluated by comparative human tumor cloning assays (HTCA) containing methylcellulose and agar. We achieved a median purity of CD34+ cells of 85.9% (range 69.8–92.9%) and a median yield of 48.1% (range 21.0–85.2%). From these data in each case the estimated log depletion of tumor cells was calculated and compared with the experimentally achieved (HTCA) log depletion (log Δ depletion = log experimental depletion − log calculated depletion). In our experiments we achieved a median depletion of 2.75 log (range 1.55–3.69 log). When corrected for CD34+ cell yield of each experiment we observed a median ‘yield corrected depletion’ of 2.38 log (range 1.48–3.15 log). The following Δ depletion values were obtained: +0.32 log (HTB 129, breast), +0.21 log (HTB 26, breast), +0.04 log (HTB 26) for experiments with higher experimental depletion, and −0.23 log (HTB 26), −0.9 log (HTB 26, PBMNC from patient with multiple myeloma), −0.82 log (HTB 131, breast) and −1.66 log (HTB 131) for lower depletion efficacy than calculated. These data suggest that depletion may depend on specific cell surface characteristics of tumor cells. Moreover, plasma factors (eg paraprotein) may also have some impact. In summary, the Isolex 50 provides a high purity of CD34+ cells and depletion of tumor cells was efficient. However, calculated and experimental purging efficiencies are not necessarily identical.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Roots-Weiß, A., Papadimitriou, C., Serve, H. et al. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems. Bone Marrow Transplant 19, 1239–1246 (1997). https://doi.org/10.1038/sj.bmt.1700812
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700812
Keywords
This article is cited by
-
Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells
Cancer Gene Therapy (2001)
-
Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial
Bone Marrow Transplantation (2000)
-
Large-scale mobilization and isolation of CD34+ cells from normal donors
Bone Marrow Transplantation (2000)